---
name: Pilot Patient SB Age 29

data:
- 
  resourceType: Patient
  name: Sally39 Bishop56
  gender: female
  birthDate: 1994-06-01
  id: Sally39Bishop56
  extension:
  -
    url: http://hl7.org/fhir/us/core/StructureDefinition/us-core-birthsex
    valueCode: F

# CIN 2 Colposcopy
-
  resourceType: DiagnosticReport
  code: LOINC#65753-6 Cervix Pathology biopsy report
  status: final
  conclusionCode:
  - SNOMEDCT#285838002 Cervical intraepithelial neoplasia grade 2 (disorder)
  effectiveDateTime: 2023-03-31

# Colposcopy  
-
  resourceType: Procedure
  code: CPT#57455 Colposcopy of the cervix including upper/adjacent vagina; with biopsy(s) of the cervix
  performedDateTime: 2023-03-31
  status: completed

# LSIL Pap Smear, Transformation Zone Absent
- 
  resourceType: DiagnosticReport
  code: LOINC#47527-7 Cytology report of Cervical or vaginal smear or scraping Cyto stain.thin prep
  status: final
  conclusionCode:
  - SNOMEDCT#62051000119105 Low grade squamous intraepithelial lesion on cervical Papanicolaou smear (finding)
  - SNOMEDCT#412716005 Cervical smear transformation zone cells absent (situation)
  effectiveDateTime: 2023-02-27

# NILM Pap Smear
- 
  resourceType: DiagnosticReport
  code: LOINC#10524-7 Microscopic observation [Identifier] in Cervix by Cyto stain
  status: final
  conclusionCode:
  - SNOMEDCT#373887005 Negative for intraepithelial lesion or malignancy (finding)
  effectiveDateTime: 2018-12-06

# LSIL Pap
- 
  resourceType: DiagnosticReport
  code: LOINC#10524-7 Microscopic observation [Identifier] in Cervix by Cyto stain
  status: final
  conclusionCode:
  - SNOMEDCT#62051000119105 Low grade squamous intraepithelial lesion on cervical Papanicolaou smear (finding)
  effectiveDateTime: 2015-10-19

# Should be Treatment of CIN2 is recommended
results:
  HasRecentAbnormalScreening: true
  ManagementRecommendation: 
    short: 'Surveillance or Treatment'
    date: '2023-12-30'
    group: 'Managing Histology (I.2)'
    details:
    -  "Treatment of CIN2 is recommended unless the patient's concerns about the effect of treatment on future pregnancy outweigh concerns about cancer."
    -  "Excisional treatment is preferred, and treatment with ablation is acceptable."
    -  "Observation is unacceptable when the squamocolumnar junction or the upper limit of the lesion is not fully visualized or when the results of an endocervical sampling, if performed, is CIN 2+ or ungraded."
    -  "Observation includes colposcopy and primary hrHPV testing or cotesting at 6-month intervals for up to 2 years."